Skip to main content
Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring logoLink to Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
. 2024 Jan 31;16(1):e12546. doi: 10.1002/dad2.12546

Correction to “Validation of 3‐ and 5‐point severity scales to assess ARIA‐E”

PMCID: PMC10831131  PMID: 38304321

Bracoud L, Klein G, Lyons M, et al. Validation of 3‐ and 5‐point severity scales to assess ARIA‐E. Alzheimer's Dement (Amst). 2023;15:e12503.

In Table 1, the formatting of the cells was incorrect and suggested that amyloid‐related imaging abnormality – edema (ARIA‐E) with the greatest lesion extent being < 5 cm and with multiple regions affected, should be categorized as 1 (Mild) using the SSAE‐3 scale; as opposed to being correctly categorized as 2 (Moderate). Please see the corrected Table 1 below.

TABLE 1.

Three‐point and 5‐point Severity Scales of ARIA‐E.

ARIA‐E extent ARIA‐E focality SSAE‐3 SSAE‐5
No ARIA‐E N/A 0 0
<5 cm Monofocal 1 (Mild) 1 (Mild)
<5 cm Multifocal 2 (Moderate) 2 (Mild+)
5–10 cm Monofocal 2 (Moderate) 3 (Moderate)
5–10 cm Multifocal 2 (Moderate) 4 (Moderate+)
>10 cm Monofocal 3 (Severe) 5 (Severe)
>10 cm Multifocal 3 (Severe) 5 (Severe)

Abbreviations: ARIA‐E, amyloid‐related imaging abnormalities – edema; N/A, not applicable; SSAE, Severity Scale of ARIA‐E.

We apologize for this error.


Articles from Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring are provided here courtesy of Wiley

RESOURCES